Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Diclofenac Formulations for Actinic Keratosis

Approved Formulations and Indications

  • The FDA-approved diclofenac topical formulation for skin conditions is 3% diclofenac sodium in 2.5% hyaluronic acid gel, which is indicated for actinic keratosis (AK) 1
  • Standard application is twice daily for 60-90 days as a field-based or lesion-directed treatment 1
  • Diclofenac gel causes less intense local skin reactions than 5-fluorouracil (5-FU) or imiquimod 5% cream, making it more tolerable but potentially less effective 1

Efficacy for Actinic Keratosis

  • Complete clearance rates with diclofenac 3% gel range from 19-50% after 90 days of treatment 1, 2
  • In comparative studies, diclofenac 3% gel showed 32% complete clearance versus 55.4% for 5-FU 0.5% in 10% salicylic acid 3
  • Extending treatment from 90 to 180 days provides only an additional 5% complete clearance without significant changes in adverse effects 1

Special Considerations by Treatment Site

  • For actinic keratosis on the face and scalp: Apply twice daily for 60-90 days 1
  • For forearm and hands: May require prolonged treatment due to thicker skin or hindrance to penetration by keratin in thicker AKs 4
  • For below the knee: Use with caution due to potential healing issues, especially in elderly patients; consider less frequent application 4

Adverse Effects and Monitoring

  • For patients with poor healing sites such as the lower leg, treatment should be undertaken with caution and may need supervision 3

Combination Therapy

  • The combination of diclofenac and cryosurgery is not recommended over cryosurgery alone 2
  • Consider alternative treatments if diclofenac is ineffective, such as 5-FU, imiquimod, or photodynamic therapy 1